Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1352
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within New Haven, Connecticut. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 625–636 of 1,352 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Recruiting No phase listed Observational

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

NCT03053193
View directory record Official record
Conditions
Breast Cancer
Interventions
MammaPrint, BluePrint, and Full-Genome Testing
Diagnostic Test
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
130
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Enrolling by invitation No phase listed Observational

Biorepository to Support Research in Kidney Diseases

NCT04343417
View directory record Official record
Conditions
Acute Kidney Injury, Acute Interstitial Nephritis, Kidney Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Active, not recruiting Not applicable Interventional

Eversense® Non-adjunctive Use Post Approval Study

NCT04836546
View directory record Official record
Conditions
Diabetes
Interventions
Blood glucose meter, Eversense CGM System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
Los Angeles, California • Englewood, Colorado • Hamden, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed No phase listed Observational

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.

NCT05567809
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

Hemodynamic-GUIDEd Management of Heart Failure

NCT03387813
View directory record Official record
Conditions
Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
Interventions
CardioMEMS™ HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
125
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

NCT02681549
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Interventions
Pembrolizumab plus Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Artificial Intelligence + Care Coach Intervention

NCT05352399
View directory record Official record
Conditions
Dementia, Caregiver, Emergency Department, Artificial Intelligence, Care Transition
Interventions
NeuViCare application
Other
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Phase 1 Interventional

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

NCT02013154
View directory record Official record
Conditions
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Interventions
DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

NCT06541678
View directory record Official record
Conditions
Healthy
Interventions
Danuglipron, Cyclosporine, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function

NCT05298774
View directory record Official record
Conditions
Gastrointestinal Diseases, Ileus Paralytic, Ileus
Interventions
G-tech WPS
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Nov 15, 2026, 4:10 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Nov 15, 2026, 4:10 PM EST